RenovoRx Overview
Latest ROE for RenovoRx: -136.82% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-136.82%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for RNXT is -136.82%. That is below the sector sector average of 11.73%. Investors often review this figure alongside RenovoRx's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, RNXT currently prints -136.82% for ROE, while the sector average sits near 11.73%. That is roughly 1266.0% below the sector mean. Large gaps often invite a closer look at RenovoRx's growth, margins, and balance sheet.
Return on Equity shows how effectively RenovoRx converts resources into returns. At -136.82%, RNXT may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting RNXT's ROE (-136.82%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
